A comparative study on efficacy of Aragvadha patra lepa vs Chakramarda beeja lepa in Dadru kushtha i.e. Dermatophytosis

A comparative clinical and antimicrobial study on efficacy of Aragvadha patra lepa vs Chakramarda beeja lepa in Dadru kushtha(Dermatophytosis) - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074292

Enrollment

Registered

2024-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient with classical sign and symptoms of Dadru Kushtha, irrespective of chronicity, recurrence or size of the lesion. Patients willing to participate.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Immunocompromised patients, HIV positive, Hepatitis- B positive, malignancy, tuberculosis. Patients suffering from Diabetes and coronary artery disease. Known history of hypersensitivity to the drugs incorporated in the study. Chronic obstructive pulmonary disease, Chronic kidney or liver disease. Any other criteria or major illnesses that investigator find inappropriate for the study were not taken. Patient on any immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
FOR INTERVENTIONAL STUDY Percentage resolution of the clinical signs and symptoms of Dadru kushtha in both the groups after 45 days and observing the Anti-microbial effect of drugs using culture and sensitivity. Timepoint: FOR INTERVENTIONAL STUDY Percentage resolution of the clinical signs and symptoms of Dadru kushtha in both the groups after 45 days i.e. follow up for 2 months and observing the Anti-microbial effect of drugs using Culture & sensitivity i.e.at baseline	—

Measure

Time frame

FOR INTERVENTIONAL STUDY Percentage resolution of the clinical signs and symptoms of Dadru kushtha in both the groups after 45 days and observing the Anti-microbial effect of drugs using culture and sensitivity. Timepoint: FOR INTERVENTIONAL STUDY Percentage resolution of the clinical signs and symptoms of Dadru kushtha in both the groups after 45 days i.e. follow up for 2 months and observing the Anti-microbial effect of drugs using Culture & sensitivity i.e.at baseline

—

Secondary

Measure	Time frame
Changes in DLQI after treatment in both the groups. The recurrence rates in both treatment groups till 105th day of the study. Incidence of adverse effects associated with each treatment modality. Timepoint: Changes in DLQI after treatment in both the groups.i.e.0th,15th,30th & 45th day. The recurrence rates in both treatment groups till 105th day of the study. Incidence of adverse effects associated with each treatment modality.	—

Measure

Time frame

Changes in DLQI after treatment in both the groups. The recurrence rates in both treatment groups till 105th day of the study. Incidence of adverse effects associated with each treatment modality. Timepoint: Changes in DLQI after treatment in both the groups.i.e.0th,15th,30th & 45th day. The recurrence rates in both treatment groups till 105th day of the study. Incidence of adverse effects associated with each treatment modality.

—

Countries

India

Contacts

Public ContactDr Dipika Yadav

All India Institute Of Ayurveda

vd.raishalini@gmail.com9389423843

Outcome results